Neuroactive Steroid Particle Sizing for Sustained Injection Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of neuroactive steroids like brexanolone and ganaxolone have short terminal half-lives and poor oral bioavailability, limiting their clinical use, and intravenous administration methods, such as ZULRESSO, are inconvenient and time-consuming.
Innovation Solution
A pharmaceutical composition comprising neuroactive steroids with specific particle sizes and excipients, administered via intramuscular or subcutaneous injection, achieving a maximum plasma concentration within 30 minutes to 6 hours and maintaining over 5% of Cmax for at least 5 days.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravenous infusion is used to administer brexanolone, then therapeutic effect is achieved, but treatment duration becomes excessively long (60 hours) and convenience deteriorates
Solution Approach 1:
The patent segments the drug delivery system into multiple particle size fractions (small particles 0.2-1.5 μm and large particles 1.5-15 μm). The small particles provide rapid absorption for quick therapeutic effect, while large particles provide sustained release for extended duration, eliminating the need for prolonged 60-hour intravenous infusion
Solution Approach 2:
The patent changes the physical parameter of particle size distribution to optimize pharmacokinetics. By controlling particle size ranges and their proportions (0.01-50% small particles, 50-99.99% large particles), the formulation achieves both rapid onset and sustained effect, resolving the contradiction between quick therapeutic effect and treatment duration
2Ease of operation
If oral administration is used for neuroactive steroids, then convenience is improved, but bioavailability remains poor
Solution Approach 1:
The patent changes the physical parameter of particle size to the micrometer range (0.2-15 μm), which significantly increases surface area to volume ratio and enhances dissolution rate. This parameter change improves oral bioavailability while maintaining the convenience of oral administration
Solution Approach 2:
The patent introduces particle size distribution as an additional dimension of control beyond chemical composition. By optimizing the dimensional parameter of particle size and its distribution, the formulation achieves enhanced bioavailability that overcomes the traditional limitation of poor oral absorption
3Quantity of substance
If particle size is reduced to enhance dissolution, then bioavailability improves, but manufacturing complexity increases
Solution Approach 1:
The patent segments the particle population into two distinct size ranges that can be produced by standard pharmaceutical milling equipment. This segmentation approach uses conventional manufacturing technology rather than requiring complex nanoscale processing, thus improving bioavailability without excessively increasing manufacturing complexity
Solution Approach 2:
The patent optimizes particle size parameters to ranges (0.2-15 μm) that are achievable with standard pharmaceutical equipment. By selecting parameter ranges that align with conventional manufacturing capabilities, the formulation enhances bioavailability while avoiding prohibitively complex manufacturing processes
Data Source
AI summary
Disclosed herein is a pharmaceutical composition comprising a pharmaceutically effective amount of a neuroactive steroid that is a positive modulator of γ aminobutyric acid type A (GABAA) receptors. Also disclosed are methods of treating diseases using the pharmaceutical composition and processes of producing the pharmaceutical composition.